From: Symptomatic remission affects employment outcomes in schizophrenia patients
 | Remission (n = 124) | Nonremission (n = 401) |  |  | |
---|---|---|---|---|---|
 | Total | Mean ± SD (n,%) | Mean ± SD (n,%) | T/Chi-square | P-value |
Age | 51.8 ± 9.84 | 49.38 ± 9.54 | 52.55 ± 9.83 | 3.17** | 0.002 |
Gender (male, %) | 343 (65.3%) | 70 (56.5%) | 273 (68.1%) | 5.65* | 0.017 |
Education (years) | 9.16 ± 3.62 | 10.7 ± 3.48 | 8.67 ± 3.53 | −5.40*** | 0.001 |
Age of schizophrenia onset (years) | 22.49 ± 6.78 | 24.22 ± 6.80 | 21.95 ± 6.69 | −3.06** | 0.002 |
PANSS | 74.32 ± 17.26 | 57.90 ± 13.4 | 79.40 ± 15.01 | 14.29*** | 0.001 |
 P | 14.27 ± 4.12 | 11.97 ± 3.42 | 14.99 ± 4.07 | 7.48*** | 0.001 |
 N | 22.79 ± 6.49 | 16.19 ± 4.07 | 24.83 ± 5.69 | 18.67*** | 0.001 |
 G | 37.26 ± 9.10 | 29.74 ± 7.12 | 39.59 ± 8.35 | 11.86*** | 0.001 |
Antipsychotics type | Â | Â | Â | 0.17 | 0.919 |
 FGA (n, %) | 200 (38.1%) | 48 (38.7%) | 152 (37.9%) |  |  |
 NC-SGA (n, %) | 182 (34.7%) | 44 (35.5%) | 138 (34.4%) |  |  |
 Clozapine (n, %) | 143 (27.2%) | 32 (25.8%) | 111 (27.7%) |  |  |
Defined daily dose of antipsychotics | 0.83 ± 0.73 | 0.72 ± 0.48 | 0.86 ± 0.79 | 2.29* | 0.023 |
MMSE | 24.98 ± 8.76 | 29.87 ± 3.88 | 23.46 ± 9.30 | −11.03*** | 0.001 |
PSP | 53.25 ± 11.30 | 62.56 ± 7.52 | 50.36 ± 10.70 | −20.04*** | 0.001 |
Initial employment type | Â | Â | Â | 36.52*** | 0.001 |
 Hospital-based workshop (n, %) | 323 (61.5%) | 48 (38.7%) | 275 (68.6%) |  |  |
 Sheltered (n, %) | 68 (13.0%) | 23 (18.5%) | 45 (11.2%) |  |  |
 Supported (n, %) | 134 (25.5%) | 53 (42.7%) | 81 (20.2%) |  |  |
Employment outcomes | |||||
 Cumulated duration (months) per year | 4.53 ± 5.31 | 7.21 ± 5.09 | 3.71 ± 5.11 | −9.38*** | 0.001 |
 Cumulated incomes (NT dollars) per year | 5005.3 ± 14,818.5 | 11,378 ± 26,836.6 | 3048.6 ± 7091.2 | −4.81*** | 0.001 |